Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Skin Wound: early-phase trial registry

1 of 6 indexed Skin Wound trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Skin Wound: 6 US clinical trials tracked, 1 recruiting.

Skin Wound is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Stratatech, a Mallinckrodt Company, running 2 of these trials.

Enrollment posture brief

Registry condition skin-wound

OPEN 1 | RECR 17% | LATE 1 | EARLY 3 | RANK #2866 | SPON 2

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Skin Wound (this)17%
Open-enrollment share among volume-matched conditions near Skin Wound

Skin Wound lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Skin Wound on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Skin Wound is recruiting below its size-band peers.

    1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Skin Wound research.

    Stratatech, a Mallinckrodt Company accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Skin Wound trials plan to enrol fewer than 100 people.

    Median target enrolment is 28 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.

  4. Skin Wound research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21Phase 31

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Skin Wound records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Wound Vac Device
1 trials
SOC Wound Covering Procedure
1 trials
Amnion Membrane Powder Drug
1 trials
NP-PWD Device
1 trials
StrataGraft Biological
1 trials
PROPRIO FOOT® by Ossur & Empower ankle by Ottobock Device
1 trials
StrataGraft Skin Tissue Biological
1 trials
Autologous Skin Fibroblasts Biological
1 trials

US sites by state

Facility locations filed on Skin Wound trials. A trial with sites in several states counts in each.

Wisconsin 2 trials
Texas 2 trials
North Carolina 2 trials
Maryland 1 trials
Indiana 1 trials
Colorado 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Skin Wound page

6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Skin Wound condition card totals 6 registered trials; most-linked intervention Wound Vac; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.